Strensiq Asfotase Alfa Research Paper

Strensiq Asfotase Alfa

Drug Overview
 Strensiq is approved by FDA on 23rd October 2015
 Brand name is Strensiq
 Generic name is asfotase alfa
 Active ingredient is asfotase alfa
 Inactive ingredients are dibasic sodium phosphate, heptahydrate, monobasic sodium phosphate, monohydrate and sodium chloride

Strensiq asfotase alfa is used as the initially endorsed treatment for perinatal, infantile and juvenile onset hypophosphatasia (HPP).
HPP is an uncommon, hereditary, progressive, metabolic disorder in which patients experience crushing impacts on numerous systems of the body, prompting serious disability and life-debilitating complications. It is characterized by imperfect bone mineralization that can leads to rickets and softening of the

The dose may be increased to 3 mg/kg three times each week for insufficient adequacy.

Adolescent Onset HPP
Recommended dosage regimen is
 2 mg/kg administered subcutaneously three times each week
 1 mg/kg regulated six times per week
Infusion site responses may limit the tolerability of the six times per week regimen.

Strensiq Side Effects
Strensiq may bring about serious side effects or reactions, including:

Hypersensitivity responses (serious allergies): Serious allergic responses have happened in a few individuals who use Strensiq. Indications of susceptible hypersensitivity reactions are:
 Trouble in breathing
 Nausea or vomiting
 Swelling of eyes, lips or tongue
 Hives
 Feeling faint or unconscious
 Dizziness
 Itching of lips, tongue or throat
Lipodystrophy that is skin thickening or pits at the infusion site
Ectopic Calcium (in eyes and kidneys)
The most well-known side incorporate local skin infusion site responses includes
 Skin red patches
 Bruising
 Color change
